Global Urological Cancer Drugs Market Research Report 2021
Global Urological Cancer Drugs Market Research Report 2021
The Urological Cancer Drugs Market report highlights technological advancements, investment opportunities, and regulatory frameworks shaping the industry landscape through 2030.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
Research Predicts that Urological Cancer Drugs Market was valued USD xxxx unit in 2020 and is expected to reach USD xxxx Unit by the year 2025, growing at a CAGR of xx% globally.
Global Urological Cancer Drugs Market Overview:
Global Urological Cancer Drugs Market Report 2020 comes with the extensive industry analysis of development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2020-2025.This research study of Urological Cancer Drugs involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Impact of COVID-19 on Urological Cancer Drugs Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affected the Urological Cancer Drugs market in 2020.
Global Urological Cancer Drugs Market Segmentation
By Type, Urological Cancer Drugs market has been segmented into:
Xofigo (Radium Ra 223 Dichloride)
Jevtana (Cabazitaxel)
Inlyta (Axitinib)
Votrient (Pazopanib Hydrochloride)
Sutent (Sunitinib Malate)
Zytiga (Abiraterone Acetate)
Xtandi (Enzalutamide)
Opdivo (Nivolumab)
Provenge (Sipuleucel-T)
By Application, Urological Cancer Drugs market has been segmented into:
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
Asia-Pacific (China, India, Japan, Southeast Asia etc.)
South America (Brazil, Argentina etc.)
Middle East & Africa (Saudi Arabia, South Africa etc.)
Top Key Players Covered in Urological Cancer Drugs market are:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
Tolmar Inc
1. Market Overview of Urological Cancer Drugs
1.1 Urological Cancer Drugs Market Overview
1.1.1 Urological Cancer Drugs Product Scope
1.1.2 Market Status and Outlook
1.2 Urological Cancer Drugs Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Urological Cancer Drugs Historic Market Size by Regions (2015-2020)
1.4 Urological Cancer Drugs Forecasted Market Size by Regions (2021-2026)
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth (2015-2026)
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Urological Cancer Drugs Sales Market by Type (2015-2026)
2.1 Global Urological Cancer Drugs Historic Market Size by Type (2015-2020)
2.2 Global Urological Cancer Drugs Forecasted Market Size by Type (2021-2026)
2.3 Xofigo (Radium Ra 223 Dichloride)
2.4 Jevtana (Cabazitaxel)
2.5 Inlyta (Axitinib)
2.6 Votrient (Pazopanib Hydrochloride)
2.7 Sutent (Sunitinib Malate)
2.8 Zytiga (Abiraterone Acetate)
2.9 Xtandi (Enzalutamide)
2.10 Opdivo (Nivolumab)
2.11 Provenge (Sipuleucel-T)
3. Covid-19 Impact Urological Cancer Drugs Sales Market by Application (2015-2026)
3.1 Global Urological Cancer Drugs Historic Market Size by Application (2015-2020)
3.2 Global Urological Cancer Drugs Forecasted Market Size by Application (2021-2026)
3.3 Prostate Cancer
3.4 Bladder Cancer
3.5 Kidney Cancer
3.6 Testicular Cancer
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Urological Cancer Drugs Production Capacity Market Share by Manufacturers (2015-2020)
4.2 Global Urological Cancer Drugs Revenue Market Share by Manufacturers (2015-2020)
4.3 Global Urological Cancer Drugs Average Price by Manufacturers (2015-2020)
5. Company Profiles and Key Figures in Urological Cancer Drugs Business
5.1 Novartis
5.1.1 Novartis Company Profile
5.1.2 Novartis Urological Cancer Drugs Product Specification
5.1.3 Novartis Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.2 Pfizer
5.2.1 Pfizer Company Profile
5.2.2 Pfizer Urological Cancer Drugs Product Specification
5.2.3 Pfizer Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.3 Johnson & Johnson
5.3.1 Johnson & Johnson Company Profile
5.3.2 Johnson & Johnson Urological Cancer Drugs Product Specification
5.3.3 Johnson & Johnson Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.4 AstraZeneca
5.4.1 AstraZeneca Company Profile
5.4.2 AstraZeneca Urological Cancer Drugs Product Specification
5.4.3 AstraZeneca Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.5 Astellas
5.5.1 Astellas Company Profile
5.5.2 Astellas Urological Cancer Drugs Product Specification
5.5.3 Astellas Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.6 Bristol-Myers Squibb
5.6.1 Bristol-Myers Squibb Company Profile
5.6.2 Bristol-Myers Squibb Urological Cancer Drugs Product Specification
5.6.3 Bristol-Myers Squibb Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.7 Abbott Laboratories
5.7.1 Abbott Laboratories Company Profile
5.7.2 Abbott Laboratories Urological Cancer Drugs Product Specification
5.7.3 Abbott Laboratories Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.8 Celgene Corporation
5.8.1 Celgene Corporation Company Profile
5.8.2 Celgene Corporation Urological Cancer Drugs Product Specification
5.8.3 Celgene Corporation Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.9 Dendreon Corporation
5.9.1 Dendreon Corporation Company Profile
5.9.2 Dendreon Corporation Urological Cancer Drugs Product Specification
5.9.3 Dendreon Corporation Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.10 Ferring Pharmaceuticals
5.10.1 Ferring Pharmaceuticals Company Profile
5.10.2 Ferring Pharmaceuticals Urological Cancer Drugs Product Specification
5.10.3 Ferring Pharmaceuticals Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.11 GlaxoSmithKline
5.11.1 GlaxoSmithKline Company Profile
5.11.2 GlaxoSmithKline Urological Cancer Drugs Product Specification
5.11.3 GlaxoSmithKline Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.12 Indevus Pharmaceuticals Inc
5.12.1 Indevus Pharmaceuticals Inc Company Profile
5.12.2 Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Specification
5.12.3 Indevus Pharmaceuticals Inc Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.13 Ipsen
5.13.1 Ipsen Company Profile
5.13.2 Ipsen Urological Cancer Drugs Product Specification
5.13.3 Ipsen Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.14 Roche Healthcare
5.14.1 Roche Healthcare Company Profile
5.14.2 Roche Healthcare Urological Cancer Drugs Product Specification
5.14.3 Roche Healthcare Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.15 Sanofi S.A.
5.15.1 Sanofi S.A. Company Profile
5.15.2 Sanofi S.A. Urological Cancer Drugs Product Specification
5.15.3 Sanofi S.A. Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.16 Tolmar Inc
5.16.1 Tolmar Inc Company Profile
5.16.2 Tolmar Inc Urological Cancer Drugs Product Specification
5.16.3 Tolmar Inc Urological Cancer Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
6. North America
6.1 North America Urological Cancer Drugs Market Size (2015-2026)
6.2 North America Urological Cancer Drugs Key Players in North America (2015-2020)
6.3 North America Urological Cancer Drugs Market Size by Type (2015-2020)
6.4 North America Urological Cancer Drugs Market Size by Application (2015-2020)
7. East Asia
7.1 East Asia Urological Cancer Drugs Market Size (2015-2026)
7.2 East Asia Urological Cancer Drugs Key Players in North America (2015-2020)
7.3 East Asia Urological Cancer Drugs Market Size by Type (2015-2020)
7.4 East Asia Urological Cancer Drugs Market Size by Application (2015-2020)
8. Europe
8.1 Europe Urological Cancer Drugs Market Size (2015-2026)
8.2 Europe Urological Cancer Drugs Key Players in North America (2015-2020)
8.3 Europe Urological Cancer Drugs Market Size by Type (2015-2020)
8.4 Europe Urological Cancer Drugs Market Size by Application (2015-2020)
9. South Asia
9.1 South Asia Urological Cancer Drugs Market Size (2015-2026)
9.2 South Asia Urological Cancer Drugs Key Players in North America (2015-2020)
9.3 South Asia Urological Cancer Drugs Market Size by Type (2015-2020)
9.4 South Asia Urological Cancer Drugs Market Size by Application (2015-2020)
10. Southeast Asia
10.1 Southeast Asia Urological Cancer Drugs Market Size (2015-2026)
10.2 Southeast Asia Urological Cancer Drugs Key Players in North America (2015-2020)
10.3 Southeast Asia Urological Cancer Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Urological Cancer Drugs Market Size by Application (2015-2020)
11. Middle East
11.1 Middle East Urological Cancer Drugs Market Size (2015-2026)
11.2 Middle East Urological Cancer Drugs Key Players in North America (2015-2020)
11.3 Middle East Urological Cancer Drugs Market Size by Type (2015-2020)
11.4 Middle East Urological Cancer Drugs Market Size by Application (2015-2020)
12. Africa
12.1 Africa Urological Cancer Drugs Market Size (2015-2026)
12.2 Africa Urological Cancer Drugs Key Players in North America (2015-2020)
12.3 Africa Urological Cancer Drugs Market Size by Type (2015-2020)
12.4 Africa Urological Cancer Drugs Market Size by Application (2015-2020)
13. Oceania
13.1 Oceania Urological Cancer Drugs Market Size (2015-2026)
13.2 Oceania Urological Cancer Drugs Key Players in North America (2015-2020)
13.3 Oceania Urological Cancer Drugs Market Size by Type (2015-2020)
13.4 Oceania Urological Cancer Drugs Market Size by Application (2015-2020)
14. South America
14.1 South America Urological Cancer Drugs Market Size (2015-2026)
14.2 South America Urological Cancer Drugs Key Players in North America (2015-2020)
14.3 South America Urological Cancer Drugs Market Size by Type (2015-2020)
14.4 South America Urological Cancer Drugs Market Size by Application (2015-2020)
15. Rest of the World
15.1 Rest of the World Urological Cancer Drugs Market Size (2015-2026)
15.2 Rest of the World Urological Cancer Drugs Key Players in North America (2015-2020)
15.3 Rest of the World Urological Cancer Drugs Market Size by Type (2015-2020)
15.4 Rest of the World Urological Cancer Drugs Market Size by Application (2015-2020)
16 Urological Cancer Drugs Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter’s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Research Methodology:
Urological Cancer Drugs Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|